勃起功能障碍
医学
阴茎假体
临床试验
他达拉非
富血小板血浆
重症监护医学
随机对照试验
佩罗尼病
加药
指南
人口
内科学
血小板
病理
环境卫生
作者
Dylan Fazekas,Katherine Campbell,Braian Ledesma,Thomas A. Masterson
标识
DOI:10.1093/sxmrev/qead032
摘要
Erectile dysfunction (ED) is the inability to achieve or maintain erection for satisfactory sexual performance. ED drastically reduces the quality of life for men and their partners and is commonly linked to comorbid conditions such as diabetes and cardiovascular disease. As a result, clinicians and researchers are working to improve treatments for ED. Current guideline-approved ED treatments include oral phosphodiesterase type 5 inhibitors, intraurethral alprostadil, penile intracavernosal injections, and penile prosthesis surgery. Today, there is increasing interest in restorative therapies such as intracavernosal platelet-rich plasma (PRP) for the management of ED.This narrative review describes the current trials investigating intracavernosal PRP for ED and proposes future directions to increase the strength of evidence to support use of PRP in this population.A comprehensive literature search of PubMed, Science Direct, and Scopus was performed to identify all randomized clinical trials using PRP for the treatment of ED.We identified 4 randomized clinical trials investigating the safety and efficacy of PRP for ED. We found significant heterogeneity among study protocols, including collection of PRP, dosing of PRP, and follow-up.While intracavernosal PRP is considered safe, its efficacy for the management of ED remains unknown due to variability among clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI